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The well-documented rise in the prevalence of type 2 diabetes (T2D) is a major global clinical
and public health challenge, as described by Juliana Chan and Andrea Luk in their accompa-
nying Perspective article [1]. Somewhat less attention has been paid to the potential for the ris-
ing global diabetes problem to widen health inequalities, and for the solutions that are put in
place to tackle the problem to worsen or improve those inequalities. Inequity is at the heart of
the diabetes problem, since 75% of cases occur in low- and middle-income countries [2]. The
impact of diabetes on emerging countries will be particularly severe as the disease is chronic,
expensive to treat, and tends to affect economically active people. The economic cost of dealing
with the consequences of diabetes is not only a threat to health systems but is a far broader eco-
nomic and social problem and thus a threat to future long-term sustainable development.
Research aimed at diabetes prevention is therefore the focus of this special issue of PLOS
Medicine.
The pattern of the incidence and prevalence of T2D between countries suggests that the dis-
order originates from a complex interaction between lifestyles, obesity, and innate susceptibil-
ity, driven by both genetic factors and developmental programming by maternal and postnatal
nutrition. The major driving force behind the contemporary rise in prevalence is a rising inci-
dence of disease driven by major secular changes in dietary and physical activity behavior. The
T2D epidemic can be viewed at several different levels. At the individual level, the interplay
between susceptibility factors and lifestyles is understood in broad terms, but our understand-
ing at the molecular level is still limited. At the level of specific populations, more is understood
about how changes in societal influences on diet and physical activity are driving the epidemic,
but much of this understanding is restricted to developed countries. Finally, at the global level,
there is a strong interconnection between the emergence of T2D and changes in the food sup-
ply and patterns of consumption, changes in transportation use, and related issues such as air
pollution and climate change [3]. At this level, T2D can be seen as a clinical manifestation of a
wider societal problem created by the undesirable consequences of rapid economic
development.
Randomized controlled trials in people at high risk of diabetes clearly demonstrate that life-
style interventions can result in an approximate halving of the risk of developing the disease,
exceeding the apparent benefit of oral diabetes drugs [4]; this impact of behavior-change pro-
grams can be sustained over the long term [5]. These studies prove that T2D is preventable but
do not directly provide information about how it should be prevented in real-world settings.
Even in developed countries, efforts to translate such research interventions into practical
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programs have met challenges, with a large gulf persisting between efficacy and effectiveness,
the gap between the health benefits that are achievable in a clinical trial as opposed to those
that are realized in the real world [6]. As an illustration, in a research article in this issue, Laura
Gray and colleagues report on a diabetes prevention trial carried out in the United Kingdom,
and their findings indicate the importance of engaging and retaining people in such prevention
programs [7].
Diabetes prevention programs that target high-risk individuals require an integration of
efforts to test for prevalent undiagnosed diabetes, as well as so-called prediabetes, and are in
essence large scale screening programs for hyperglycemia and diabetes. In the short term, inte-
grated screening programs will increase costs as patients with newly diagnosed diabetes are
identified alongside people with prediabetes who require monitoring and follow-up. In the lon-
ger term, this type of integrated program may be cost-effective, but this still remains to be dem-
onstrated. Such approaches to prevention need to be focused on a relatively small group of
people at high absolute risk. Attempts to provide individual-level prevention interventions to
large groups of people at moderately elevated risk are not likely to be cost-effective [8]. There is
also a concern that inequalities in health could be widened by individual-level interventions
because, in general, more affluent people tend to be more likely to accept invitations for screen-
ing and treatment [9].
There is no universal recommendation on whether a country should or should not adopt
such a clinical approach to diabetes prevention, as investment would need to be considered in
competition with other clinical priorities. It is difficult to see how under-resourced health care
systems could switch clinical investment to individual-level prevention when they are failing to
meet the demands to provide systematic care and treatment to people with diabetes or its com-
plications. In such settings, calls to screen for hyperglycemia run the risk of swamping health
care systems that are already struggling to provide care. In the face of ageing populations,
health care systems globally will struggle to cope with treating the estimated 642 million people
with diagnosed diabetes anticipated by 2040 [2]. To countenance trying to provide individual-
ized preventive interventions to a further half a billion people who by then will have prediabe-
tes would put those health systems under unbearable pressure and would be an unsustainable
proposition.
Thus, as a complement to individualized approaches to prevention, there needs to be a con-
siderable scaling up of research into the societal determinants of diabetes, and evaluation of
solutions that tackle the root causes of the problem, which are fundamental shifts in popula-
tion-level dietary and physical activity behavior. As discussed by Martin White in a Perspective
in this issue of PLOS Medicine [10], the nature of the evidence base supporting these popula-
tion-level solutions will be fundamentally different from that which underpins clinical inter-
ventions, because randomized controlled trials are unlikely to be undertaken and most studies
will be quasiexperimental or observational. This evidence base is beginning to emerge—as an
example, the research article from Lindsey Smith Taillie and colleagues in this special issue
presents an analysis of the effects of a tax on nonessential energy-dense foods enacted in
Mexico [11].
At present, the evidence base for public health approaches to diabetes prevention is domi-
nated by research from developed countries. However, it is likely that population-based
approaches will be even more important in relatively resource-poor countries because health
care systems will not be able to afford prevention programs targeting high-risk individuals. Yet
the evidence base for population-based approaches to diabetes prevention in developing coun-
tries is limited and needs to be generated specifically in those contexts, as solutions cannot be
exported from developed countries. Given the economic circumstances of the countries in
which the diabetes epidemic is most pressing, there needs to be much greater investment in
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development of the evidence base for sustainable solutions that narrow inequalities, are eco-
nomically affordable, support rather than hinder economic development, and can bring about
the long-term changes in public health outcomes that are so urgently required.
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